Cancer

Novellia Data Shown to Optimize Risk Profiling to Inform HER2+ Breast Cancer Care

 -- New research demonstrates integrating AI-enabled, health record data insights with targeted educational interventions can enhance understanding and management of…

1 year ago

b.well Connected Health Names Sara Zywicki as Chief Product Officer

BALTIMORE, Dec. 12, 2024 /PRNewswire/ -- b.well Connected Health, the leading platform for unified consumer health experiences, announced today that Sara…

1 year ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Journal is the official publication of the International Union of Immunological SocietiesMarlborough, Massachusetts--(Newsfile Corp. - December 12, 2024) - Phio…

1 year ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Two of three patients achieved both complete remission and MRD-negative statusHigh response rates observed in earlier studies continue in ongoing…

1 year ago

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth…

1 year ago

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that…

1 year ago

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS…

1 year ago

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering…

1 year ago

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy…

1 year ago